======= FLI1 =======
== Gene Information ==
* **Official Symbol**: FLI1
* **Official Name**: Fli-1 proto-oncogene, ETS transcription factor
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=2313|2313]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q01543|Q01543]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=FLI1&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20FLI1|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/193067|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: This gene encodes a transcription factor containing an ETS DNA-binding domain. The gene can undergo a t(11;22)(q24;q12) translocation with the Ewing sarcoma gene on chromosome 22, which results in a fusion gene that is present in the majority of Ewing sarcoma cases. An acute lymphoblastic leukemia-associated t(4;11)(q21;q23) translocation involving this gene has also been identified. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2012].
* **UniProt Summary**: Sequence-specific transcriptional activator (PubMed:24100448, PubMed:26316623, PubMed:28255014). Recognizes the DNA sequence 5'-C[CA]GGAAGT-3'. {ECO:0000269|PubMed:24100448, ECO:0000269|PubMed:26316623, ECO:0000269|PubMed:28255014}.
|Ets|
|SAM PNT|
|megakaryocyte development|
|megakaryocyte differentiation|
|bone cell development|
|myeloid cell development|
|RNA polymerase II distal enhancer sequence-specific DNA binding|
|bone development|
|myeloid cell differentiation|
|nuclear body|
|hemostasis|
|blood circulation|
|chromatin binding|
|circulatory system process|
|DNA-binding transcription activator activity, RNA polymerase II-specific|
|skeletal system development|
|regulation of body fluid levels|
|RNA polymerase II proximal promoter sequence-specific DNA binding|
|hemopoiesis|
|hematopoietic or lymphoid organ development|
|immune system development|
|DNA-binding transcription factor activity|
|animal organ morphogenesis|
|positive regulation of transcription by RNA polymerase II|
|DNA binding|
|positive regulation of transcription, DNA-templated|
|DNA-binding transcription factor activity, RNA polymerase II-specific|
|positive regulation of nucleic acid-templated transcription|
|positive regulation of RNA biosynthetic process|
|cell development|
|positive regulation of RNA metabolic process|
|positive regulation of nucleobase-containing compound metabolic process|
|positive regulation of macromolecule biosynthetic process|
|system process|
|positive regulation of cellular biosynthetic process|
|positive regulation of gene expression|
|positive regulation of biosynthetic process|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp500|LY2090314 0.003μM R08 exp500 no dilution day6]]|-2.67|
|[[:results:exp365|I-BRD9 4μM R07 exp365]]|-2.42|
|[[:results:exp429|Rapamycin 0.001μM R08 exp429]]|-2.19|
|[[:results:exp308|Rapamycin 2μM plus FK-506 5μM R07 exp308]]|-2.02|
|[[:results:exp483|FTY720 3μM R08 exp483]]|-1.95|
|[[:results:exp413|THZ531 0.11 to 0.175μM on day4 R07 exp413]]|-1.93|
|[[:results:exp115|A-366 10μM R03 exp115]]|-1.91|
|[[:results:exp229|Dimethyloxaloylglycine 100μM R05 exp229]]|-1.91|
|[[:results:exp29|Rapamycin 1μM R00 exp29]]|-1.83|
|[[:results:exp242|Radicicol 0.16μM R05 exp242]]|-1.82|
|[[:results:exp410|THZ531 0.11 to 0.125μM on day4 R07 exp410]]|-1.8|
|[[:results:exp434|Vemurafenib 6.6μM R08 exp434]]|-1.8|
|[[:results:exp306|Rapamycin 2μM R07 exp306]]|-1.78|
|[[:results:exp432|YM155 0.001μM R08 exp432]]|-1.77|
|[[:results:exp81|Selumetinib 20μM R02 exp81]]|-1.76|
|[[:results:exp470|Chloroquine 32μM R08 exp470]]|-1.76|
|[[:results:exp220|BAY-598 4μM R05 exp220]]|-1.75|
|[[:results:exp83|Trametinib 10μM R02 exp83]]|-1.75|
|[[:results:exp347|Cyclosporin-A 0.8μM R07 exp347]]|-1.73|
|[[:results:exp277|Curcumin 6.5μM R06 exp277]]|-1.72|
|[[:results:exp344|Chlorpromazine 10μM R07 exp344]]|-1.7|
|[[:results:exp234|Ethanol 0.01 R05 exp234]]|-1.7|
|[[:results:exp317|Geldanamycin 0.015 to 0.05μM on day4 R07 exp317]]|-1.7|
|[[:results:exp504|MK2206 4μM R08 exp504]]|-1.7|
|[[:results:exp34|Rotenone 20μM R00 exp34]]|1.81|
|[[:results:exp226|Cerivastatin 0.15μM R05 exp226]]|1.92|
|[[:results:exp282|Fluvastatin 2.2μM R06 exp282]]|1.98|
|[[:results:exp114|A-196 10μM R03 exp114]]|2.06|
|[[:results:exp106|UM131593 0.2μM R03 exp106]]|2.6|
^Gene^Correlation^
|[[:human genes:m:med23|MED23]]|0.548|
|[[:human genes:c:ccdc101|CCDC101]]|0.536|
|[[:human genes:e:erg|ERG]]|0.526|
|[[:human genes:z:znf319|ZNF319]]|0.511|
|[[:human genes:h:hars|HARS]]|0.511|
|[[:human genes:l:lmo2|LMO2]]|0.493|
|[[:human genes:z:zbtb44|ZBTB44]]|0.49|
|[[:human genes:x:xpot|XPOT]]|0.488|
|[[:human genes:z:zfx|ZFX]]|0.483|
|[[:human genes:h:hdac8|HDAC8]]|0.47|
|[[:human genes:t:taf5l|TAF5L]]|0.467|
|[[:human genes:x:xpo6|XPO6]]|0.467|
|[[:human genes:r:rnmt|RNMT]]|0.467|
|[[:human genes:m:maml1|MAML1]]|0.463|
|[[:human genes:m:mllt1|MLLT1]]|0.46|
|[[:human genes:c:cbfb|CBFB]]|0.451|
|[[:human genes:m:med16|MED16]]|0.448|
|[[:human genes:m:mef2c|MEF2C]]|0.446|
|[[:human genes:t:tle4|TLE4]]|0.441|
|[[:human genes:d:dnajc3|DNAJC3]]|0.436|
|[[:human genes:m:med13|MED13]]|0.434|
|[[:human genes:t:tada1|TADA1]]|0.434|
|[[:human genes:i:irf2bp2|IRF2BP2]]|0.432|
|[[:human genes:t:taf6l|TAF6L]]|0.43|
|[[:human genes:t:tmed10|TMED10]]|0.429|
|[[:human genes:s:sox7|SOX7]]|0.428|
|[[:human genes:d:dpagt1|DPAGT1]]|0.428|
|[[:human genes:d:dhx29|DHX29]]|0.427|
|[[:human genes:l:ldb1|LDB1]]|0.426|
|[[:human genes:s:ssbp2|SSBP2]]|0.426|
|[[:human genes:d:ddx5|DDX5]]|0.425|
|[[:human genes:u:ube2l3|UBE2L3]]|0.423|
|[[:human genes:t:tcf4|TCF4]]|0.423|
|[[:human genes:l:lsmd1|LSMD1]]|0.416|
|[[:human genes:v:vmp1|VMP1]]|0.41|
|[[:human genes:d:dcaf7|DCAF7]]|0.409|
|[[:human genes:b:brpf1|BRPF1]]|0.408|
|[[:human genes:o:otud5|OTUD5]]|0.407|
|[[:human genes:g:gmppb|GMPPB]]|0.406|
|[[:human genes:b:btaf1|BTAF1]]|0.406|
|[[:human genes:r:rptor|RPTOR]]|0.405|
|[[:human genes:h:hmgb2|HMGB2]]|0.404|
|[[:human genes:z:znf592|ZNF592]]|0.404|
|[[:human genes:t:trmt10a|TRMT10A]]|0.403|
|[[:human genes:g:gtf3c2|GTF3C2]]|0.402|
|[[:human genes:b:bcl7a|BCL7A]]|0.402|
|[[:human genes:m:med13l|MED13L]]|0.401|
|[[:human genes:l:ldlrap1|LDLRAP1]]|0.401|
|[[:human genes:b:brd9|BRD9]]|0.4|
Global Fraction of Cell Lines Where Essential: 4/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|1/28|
|bone|3/26|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/16|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 3113
* **Expression level (log2 read counts)**: 6.49
{{:chemogenomics:nalm6 dist.png?nolink |}}